{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:18:24Z","timestamp":1787894304550,"version":"build-2784847793"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetes patients often exhibit suboptimal efficacy and adverse reactions, accompanied by pharmacokinetic (PK) changes, indicating drug-metabolizing enzymes and transporters (DMET) activities may change. This study aimed to determine whether type 2 diabetes affects DMET activities and quantify impact magnitude. Furthermore, gut microbiome, pharmacogenetic and demographic characteristics were assessed to elucidate the sources of inter-individual variability (IIV) in DMET activities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The activities of CYP3A and transporters P-gp, OATP and BCRP were evaluated in type 2 diabetes patients and healthy volunteers (HVs) following a single oral dose of five probe drugs (midazolam, dabigatran etexilate, pitavastatin, rosuvastatin, and atorvastatin). Population pharmacokinetics (PopPK) and an exploratory machine learning (ML) analysis were employed to quantify the impact of type 2 diabetes on DMET activities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Based on observed PK parameters, compared to HVs, type 2 diabetes patients exhibited increased exposure to midazolam (1.38-fold), dabigatran (1.40-fold), and atorvastatin (1.93-fold), whereas pitavastatin (0.931-fold) and rosuvastatin (1.25-fold) showed no change. PopPK analysis revealed that the mean activities of CYP3A and P-gp were potentially decreased by 23% and 27%, respectively, in type 2 diabetes patients, while no changes for OATP and BCRP. Notably, unlike the direct patient population covariate for P-gp, reduced CYP3A activity was indirectly estimated from lower\n                      <jats:italic>Salmonella<\/jats:italic>\n                      abundance. Additionally, factors such as sex, BCRP genotype, and\n                      <jats:italic>Clostridium_XlVb<\/jats:italic>\n                      partly explained the IIV in probe drugs exposure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings regarding altered DMET activities and identified influence factors help to identify specific drug classes that may warrant closer clinical attention in type 2 diabetes patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1924307","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:34:25Z","timestamp":1787891665000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A microdose cocktail and population pharmacokinetic study suggests potentially reduced CYP3A and P-gp activities in type 2 diabetes"],"prefix":"10.3389","volume":"17","author":[{"given":"Yafen","family":"Li","sequence":"first","affiliation":[{"name":"Drug Clinical Trial Center, Peking University Third Hospital","place":["Beijing, China"]},{"name":"Department of Endocrinology and Metabolism, Peking University Third Hospital","place":["Beijing, China"]},{"name":"Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enda","family":"Zhou","sequence":"additional","affiliation":[{"name":"Drug Clinical Trial Center, Peking University Third Hospital","place":["Beijing, China"]},{"name":"Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo","family":"Geng","sequence":"additional","affiliation":[{"name":"Drug Clinical Trial Center, Peking University Third Hospital","place":["Beijing, China"]},{"name":"Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Lei","sequence":"additional","affiliation":[{"name":"Drug Clinical Trial Center, Peking University Third Hospital","place":["Beijing, China"]},{"name":"Department of Pulmonary and Critical Care Medicine, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Yao","sequence":"additional","affiliation":[{"name":"Drug Clinical Trial Center, Peking University Third Hospital","place":["Beijing, China"]},{"name":"Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Feng","sequence":"additional","affiliation":[{"name":"Drug Clinical Trial Center, Peking University Third Hospital","place":["Beijing, China"]},{"name":"Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyan","family":"Jin","sequence":"additional","affiliation":[{"name":"Drug Clinical Trial Center, Peking University Third Hospital","place":["Beijing, China"]},{"name":"Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Kong","sequence":"additional","affiliation":[{"name":"Drug Clinical Trial Center, Peking University Third Hospital","place":["Beijing, China"]},{"name":"Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Hu","sequence":"additional","affiliation":[{"name":"Drug Clinical Trial Center, Peking University Third Hospital","place":["Beijing, China"]},{"name":"Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liang","sequence":"additional","affiliation":[{"name":"Drug Clinical Trial Center, Peking University Third Hospital","place":["Beijing, China"]},{"name":"Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Li","sequence":"additional","affiliation":[{"name":"Drug Clinical Trial Center, Peking University Third Hospital","place":["Beijing, China"]},{"name":"Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Ping","family":"Yang","sequence":"additional","affiliation":[{"name":"Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianpei","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyang","family":"Liu","sequence":"additional","affiliation":[{"name":"Drug Clinical Trial Center, Peking University Third Hospital","place":["Beijing, China"]},{"name":"Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1161\/CIRCULATIONAHA.123.064556","article-title":"Development and validation of the DOAC score: a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants","volume":"148","author":"Aggarwal","year":"2023","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/FTD.0b013e318241ac71","article-title":"The concentration of cyclosporine metabolites is significantly lower in kidney transplant recipients with diabetes mellitus","volume":"34","author":"Akhlaghi","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","article-title":"Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease","volume":"64","author":"Angiolillo","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"B5","doi-asserted-by":"publisher","first-page":"105237","DOI":"10.1016\/j.ejps.2020.105237","article-title":"Systematic external evaluation of published population pharmacokinetic models for tacrolimus in adult liver transplant recipients","volume":"145","author":"Cai","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1046\/j.1365-2125.1999.00912.x","article-title":"A pharmacokinetic model for alpha interferon administered subcutaneously","volume":"47","author":"Chatelut","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.xphs.2018.02.023","article-title":"Microdosing cocktail assay development for drug-drug interaction studies","volume":"107","author":"Chavez-Eng","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1124\/dmd.122.000906","article-title":"Antibiotics-induced disruption of gut microbiota increases systemic exposure of clopidogrel active metabolite in type 2 diabetic rats","volume":"50","author":"Chen","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"B9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s40168-023-01578-y","article-title":"Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1","volume":"11","author":"Degraeve","year":"2023","journal-title":"Microbiome"},{"key":"B10","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s11095-023-03507-y","article-title":"A hybrid algorithm combining population pharmacokinetic and machine learning for isavuconazole exposure prediction","volume":"40","author":"Destere","year":"2023","journal-title":"Pharm. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/j.1745-7254.2008.00858.x","article-title":"Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats","volume":"29","author":"Dong","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"B12","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/j.1476-5381.2011.01270.x","article-title":"Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus","volume":"163","author":"Dostalek","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/11632690-000000000-00000","article-title":"Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes","volume":"51","author":"Dostalek","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1021\/jf4007505","article-title":"The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2\/BCRP)","volume":"61","author":"Gonz\u00e1LEZ-Sarr\u00edAS","year":"2013","journal-title":"J. Agric. Food Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/cpt.1496","article-title":"Modulation of CYP450 activities in patients with type 2 diabetes","volume":"106","author":"Gravel","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"102590","DOI":"10.1016\/j.ebiom.2019.11.051","article-title":"Role of gut microbiota in type 2 diabetes pathophysiology","volume":"51","author":"Gurung","year":"2020","journal-title":"EBioMedicine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/1479164111420890","article-title":"Variability of clopidogrel response in patients with type 2 diabetes mellitus","volume":"8","author":"Hall","year":"2011","journal-title":"Diab Vasc. Dis. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/cpt.3577","article-title":"Machine learning for prediction of drug concentrations: application and challenges","volume":"117","author":"Huang","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/cts.12785","article-title":"Enhanced characterization of drug metabolism and the influence of the intestinal microbiome: a pharmacokinetic, microbiome, and untargeted metabolomics study","volume":"13","author":"Jarmusch","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40262-014-0230-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of clopidogrel","volume":"54","author":"Jiang","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/cpt.3546","article-title":"Microdose cocktail study reveals the activity and key influencing factors of OATP1B, P-Gp, BCRP, and CYP3A in end-stage renal disease patients","volume":"117","author":"Kong","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1042\/cs20160203","article-title":"Urea, a true uremic toxin: the empire strikes back","volume":"131","author":"Lau","year":"2017","journal-title":"Clin. Sci. (Lond)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40262-024-01383-2","article-title":"Development of a physiologically based pharmacokinetic population model for diabetic patients and its application to understand disease-drug-drug interactions","volume":"63","author":"Li","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00003088-200342010-00003","article-title":"Role of P-glycoprotein in pharmacokinetics: clinical implications","volume":"42","author":"Lin","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1124\/dmd.111.043513","article-title":"Combined contributions of impaired hepatic CYP2C11 and intestinal breast cancer resistance protein activities and expression to increased oral glibenclamide exposure in rats with streptozotocin-induced diabetes mellitus","volume":"40","author":"Liu","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"B26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport--an update","volume":"17","author":"Mao","year":"2015","journal-title":"Aaps J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00228-002-0528-4","article-title":"Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus","volume":"58","author":"Marques","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0021-9681(83)90093-0","article-title":"A pharmaceutical profile of diabetic patients","volume":"36","author":"Rendell","year":"1983","journal-title":"J. Chronic Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"Jama"},{"key":"B31","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/cpt.1998","article-title":"A microdose cocktail to evaluate drug interactions in patients with renal impairment","volume":"109","author":"Tatosian","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/psp4.13313","article-title":"Comparing scientific machine learning with population pharmacokinetic and classical machine learning approaches for prediction of drug concentrations","volume":"14","author":"Valderrama","year":"2025","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1124\/dmd.118.085902","article-title":"Prediction of atorvastatin pharmacokinetics in high-fat diet and low-dose streptozotocin-induced diabetic rats using a semiphysiologically based pharmacokinetic model involving both enzymes and transporters","volume":"47","author":"Wang","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"B35","doi-asserted-by":"publisher","first-page":"114142","DOI":"10.1016\/j.bcp.2020.114142","article-title":"Type 2 diabetes mellitus decreases systemic exposure of clopidogrel active metabolite through upregulation of P-glycoprotein in rats","volume":"180","author":"Yao","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1124\/dmd.122.000907","article-title":"Significance of basal membrane permeability of epithelial cells in predicting intestinal drug absorption","volume":"51","author":"Yoshitomo","year":"2023","journal-title":"Drug Metab. Dispos."},{"key":"B37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/aps.2011.33","article-title":"Tissue-specific alterations in expression and function of P-glycoprotein in streptozotocin-induced diabetic rats","volume":"32","author":"Zhang","year":"2011","journal-title":"Acta Pharmacol. Sin."},{"key":"B39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1691\/ph.2013.2742","article-title":"CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics","volume":"68","author":"Zhou","year":"2013","journal-title":"Pharmazie"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1924307\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:34:29Z","timestamp":1787891669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1924307\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":39,"alternative-id":["10.3389\/fphar.2026.1924307"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1924307","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"1924307"}}